CoChat
Sign Up
Cited by 318Inhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAdvanced Drug Delivery Systems

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Pandey, Rajesh, Khuller, G.K.·2005·Tuberculosis
DOI 10.1016/j.tube.2004.11.003
Open this paper in CoChat — free account

Abstract

The present study was planned to evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis. The SLPs prepared by the "emulsion solvent diffusion" technique possessed a favourable mass median aerodynamic diameter suitable for bronchoalveolar drug delivery. Following a single nebulization to guinea pigs, therapeutic drug concentrations were maintained in the plasma for 5 days and in the organs (lungs, liver and spleen) for 7 days whereas free drugs were cleared by 1-2 days. The mean residence time and drug bioavailability were improved several-fold in the case of drug-loaded SLPs. A similar pharmacokinetic profile was observed in Mycobacterium tuberculosis-infected guinea pigs. On nebulization of drug-loaded SLPs to infected guinea pigs at every 7th day, no tubercle bacilli could be detected in the lungs/spleen after 7 doses of treatment whereas 46 daily doses of orally administered drugs were required to obtain an equivalent therapeutic benefit. Further, there was no evidence of any biochemical hepatotoxicity. Thus, nebulization of SLP-based antitubercular drugs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.

Integrity signals

Registry

Crossref · 10.1016/j.tube.2004.11.003

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Solid lipid nanoparticles made up of stearic acid may be used as potential delivery vehicles for INH, RIF, and PZA.

    “In a similar approach, Pandey and Kuller demonstrated that SLNs made up of stearic acid may also be used as potential delivery vehicles for INH, RIF, and PZA.”

    From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [217]

  • Pulmonary delivery of drugs encapsulated in solid lipid nanoparticles through nebulization resulted in specific deposition in the lungs and detection of the drug in other organs for up to 7 days.

    “The pulmonary delivery of drugs encapsulated in SLNs through nebulization resulted in specific deposition in the lungs and the detection of the drug in other organs for up to 7 days.217”

    From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [217]

  • All these formulations showed sustained release for up to 72 h with an initial burst drug release pattern of less than 20% in the first 6 h.

    “Interestingly, all these formulations showed sustained release for up to 72 h with an initial burst drug release pattern of less than 20% in the first 6 h.”

    From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [217]

  • Researchers have developed nebulized solid lipid particles and sodium alginate nanoparticles incorporating rifampicin, isoniazid and pyrazinamide to improve targeted bioavailability in the lungs and reduce hepatotoxicity.

    “Researchers have developed nebulized solid lipid particles 129 and sodium alginate nanoparticles 130 incorporating rifampicin, isoniazid and pyrazinamide to improve targeted bioavailability in the lungs and reduce hepatotoxicity.”

    From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [129]

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Pandey, R., & Khuller, G. K.
Affiliations
Post Graduate Institute of Medical Education and Research (IN)
Corresponding author
Khuller, G.K.
ORCID
Pandey, Rajesh
Venue
Tuberculosis
Publisher
Elsevier BV
Published
2005-07
Volume
85
Issue
4
Pages
227-234
ISSN
1472-9792 (ISSN-L)
DOI
10.1016/j.tube.2004.11.003
OpenAlex
W2137397041
Cited by
318
References
24
Citations by year
2026: 5 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 18 · 2019: 19 · 2018: 24 · 2017: 18 · 2016: 24 · 2015: 13 · 2014: 26 · 2013: 20 · 2012: 14
FWCI
7.42
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Tuberculosis (publishedVersion)
  • PubMed (publishedVersion)
Funders
Department of Science and Technology, Ministry of Science and Technology, India
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
solid lipid particles, pulmonary tuberculosis, nebulized drug delivery, rifampicin, isoniazid, pyrazinamide, antitubercular agents, emulsion solvent diffusion, aerosol drug delivery, pharmacokinetics, drug bioavailability, Mycobacterium tuberculosis, guinea pig model, hepatotoxicity
MeSH terms
Administration, Inhalation, Animals, Antitubercular Agents, Biological Availability, Drug Carriers, Guinea Pigs, Isoniazid, Lipids, Pyrazinamide, Rifampin, Tuberculosis, Drug Delivery Systems, Area Under Curve, Nanostructures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review